3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
196
Myelodysplastic Syndromes
128
Precursor Cell Lymphoblastic Leukemia-Lymphoma
123
Leukemia, Lymphocytic, Chronic, B-Cell
102
Leukemia
102
Lymphoma
86
Multiple Myeloma
81
Lymphoma, Non-Hodgkin
80
Hematologic Neoplasms
65
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
62
Hodgkin Disease
62
Recurrence
52
Lymphoma, B-Cell
40
Lymphoma, Mantle-Cell
39
Myeloproliferative Disorders
36
Lymphoma, Follicular
35
Melanoma
34
Lymphoma, Large B-Cell, Diffuse
31
Burkitt Lymphoma
31
Graft vs Host Disease
28
Neoplasms, Plasma Cell
24
Primary Myelofibrosis
23
Ovarian Neoplasms
23
Lymphoma, B-Cell, Marginal Zone
23
Anemia, Refractory, with Excess of Blasts
21
Leukemia, Myelomonocytic, Chronic
20
Leukemia, Biphenotypic, Acute
17
Lymphoma, T-Cell
16
Neuroblastoma
15
Neoplasms
14
Interventions
Rituximab
7
Valganciclovir
5
Valacyclovir
3
Gemcitabine
3
Dexamethasone
3
Cisplatin
3
spartalizumab
2
pegaspargase
2
Radiotherapy, Intensity-Modulated
2
Methylprednisolone
2
Lenalidomide
2
Etoposide
2
Doxorubicin
2
Cell Count
2
Blood Specimen Collection
2
valomaciclovir
1
toripalimab
1
ruxolitinib
1
pembrolizumab
1
merphos
1
fludarabine
1
dehydroftorafur
1
avelumab
1
apatinib
1
Zidovudine
1
Watchful Waiting
1
Valproic Acid
1
Vaccines
1
Tenofovir
1
Tegafur
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Epstein-Barr Virus Infections
×
fludarabine
×
Clear all
NCT06224049
2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1
Recruiting
6 enrolled